Sorbent Therapeutics

What Sorbent Therapeutics does

Sorbent is an Australian consumer tissue and hygiene products brand owned by Solaris Paper Pty Ltd (ABN 41 126 825 769), serving Australian consumers since 1952. The company manufactures and distributes a portfolio of toilet paper (3-ply and 4-ply variants including Value Range, Silky White, Hypo-Allergenic, Double Length, and Super Size), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare dermatologically-tested line plus standard Silky White tissues). Core technology centers on tissue paper manufacturing from sustainably sourced wood pulp derived from Eucalyptus and Acacia plantations with a 6-8 year growth cycle, full PEFC chain-of-custody certification, and flushable wipes engineered to meet the AS/NZS 5328:2022 standard for dispersibility under turbulent flow.

The business operates a dual-channel go-to-market model combining broad retail distribution through Australian supermarket chains, pharmacies, convenience stores, and Amazon marketplace with a direct-to-consumer Shopify storefront at sorbent.com. Pricing is not publicly disclosed and is effectively set by retail partners; the brand monetizes through consumer packaged goods hardware sales across multiple pack sizes and price tiers targeting general consumers, sensitive-skin users, premium/enhanced-care buyers, and parents with young children. Sub-brands include Sorbent DermaCare (dermatologically tested facial tissues), Sorbent Kids (Lenny the Lion-branded wipes for children), and Sorbent Value Range (budget-friendly bulk packs).

Sorbent is privately held with no disclosed parent holding company beyond Solaris Paper Pty Ltd, no venture or private equity backers, and no public listing. A trans-Tasman data processing affiliate relationship with Cottonsoft Ltd in New Zealand is the only disclosed corporate linkage. The company holds no patents or trademarks documented in the available material and has no public awards or recognition listed. Operational signals indicate an actively operating brand with sustained product launches, retail distribution, and consumer-facing digital marketing, but no disclosed financial scale, headcount, or growth metrics.

Name

Sorbent Therapeutics

Legal name

Solaris Paper Pty Ltd

Website

https://sorbent.com

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

11–50 employees

Short description

Sorbent is an Australian consumer tissue brand owned by Solaris Paper Pty Ltd, producing toilet paper, facial tissues, and flushable wipes from PEFC-certified sustainable wood pulp for retail and direct-to-consumer sales across Australia since 1952.

Ownership category

akta.pro rank

Product category

Kidney Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Miscellaneous Chemical Products (2890)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

akta.pro secondary industry

Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring) (HLAHAKAK)

Keywords

• Kidney disease therapeutics
• Polymer drug delivery
• Fluid retention therapy
• Cardiorenal therapeutics
• Nephrology drug development

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Consumer Tissue Products: Sorbent generates revenue through the sale of toilet paper, facial tissues, and flushable wipes to consumers via retail distribution (supermarkets, pharmacies, convenience stores) and direct e-commerce. Products are sold in various pack configurations (4-pack to 48-pack) at different price points to serve value-seeking and premium segments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Sorbent Therapeutics develops fluid-retaining polymers intended as therapeutics for kidney disease. The company's core product platform consists of proprietary, non-absorbed polymers designed to bind fluid and electrolytes in the gastrointestinal tract for the management of fluid overload in renal and cardiorenal indications.

Product overview

Sorbent is an Australian consumer tissue and hygiene products company offering a comprehensive portfolio of toilet paper, facial tissues, and flushable wipes. The product lineup includes three main categories: toilet paper products (Value Range, Silky White Standard Length, Hypo-Allergenic, Double Length, and Super Size 4-ply), flushable wipes (Silky White, Hypo-Allergenic, Intimate, and Kids variants), and facial tissues (DermaCare line with Thick & Large, Ultra-Soft, and Hypo-Allergenic options, plus standard Silky White tissues). The company has been serving Australians since 1952, emphasizing sustainability with PEFC-certified materials and zero deforestation policy. Sorbent's products are designed for comfort, skin sensitivity, and environmental responsibility.

Differentiator

Problem solved

Functional benefit

Brands

• Sorbent DermaCare: Dermatologically tested facial tissues designed to help reduce risk of skin sensitivity for frequent use.
• Sorbent Kids
• Sorbent Value Range

Products and services

• Fluid-retaining polymer therapeutics (kidney disease)

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Cottonsoft LtdminorOthersNew Zealand-based affiliated company under Solaris Paper parent. Customer personal information may be transferred to Cottonsoft for the same purposes described in Sorbent's privacy policy. This is a data processing partnership for cross-border customer data management rather than a product or commercial partnership.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca: AstraZeneca markets Lokelma (sodium zirconium cyclosilicate) for hyperkalemia, directly competing in Sorbent Therapeutics' core renal indication. As a broad incumbent with deep commercial infrastructure in CKD, it is the most relevant large-pharma competitor in the same disease space.
• Otsuka Pharmaceutical: Otsuka markets tolvaptan (Jinarc) for autosomal dominant polycystic kidney disease (ADPKD), making it a relevant broad incumbent in the renal therapeutics space with a focus on slowing CKD progression — strategically adjacent to Sorbent Therapeutics' kidney disease focus.

Emerging players

• FibroGen: FibroGen developed roxadustat, an HIF-PH inhibitor for anemia in CKD. The overlap in renal disease therapeutics, particularly for CKD complications, makes it a relevant comparable peer in the broader nephrology development space.

Direct peers

• Akebia Therapeutics: Akebia developed vadadustat, an oral HIF inhibitor for anemia in CKD. As a clinical-to-commercial stage renal-focused biotech, Akebia represents a comparable trajectory and strategic positioning to Sorbent Therapeutics in the nephrology specialty pharma category.
• Ardelyx: Ardelyx is a nephrology-focused specialty pharma that developed tenapanor for hyperphosphatemia in CKD and IBS-C. Its single-therapeutic-area focus on renal disease and small-molecule approach makes it a close comparable in strategic positioning to Sorbent Therapeutics.
• Relypsa: Relypsa developed patiromer (Veltassa), a non-absorbed polymer for hyperkalemia in CKD patients — the most direct comparable to Sorbent Therapeutics' polymer-based renal therapeutics platform. Relypsa was acquired by Galenica Group in 2016 for approximately $1.53B, validating the commercial potential of polymer-based renal drugs.
• Keryx Biopharmaceuticals: Keryx developed and commercialized ferric citrate (Auryxia) for hyperphosphatemia and iron-deficiency anemia in CKD. As a CKD-focused specialty pharma that progressed from clinical development to commercialization, it represents a comparable end-state benchmark for Sorbent Therapeutics.
• Tricida: Tricida developed veverimer, a non-absorbed polymer designed to treat metabolic acidosis in CKD — directly comparable to Sorbent Therapeutics' non-absorbed polymer approach to renal disease. Its single-asset polymer focus and clinical-stage profile mirror Sorbent's structure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/sorbent
• LinkedInlinkedin.com/company/sorbent-therapeutics-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sorbent Therapeutics